PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
25.8K / 3.59M (Avg.)
-1.57 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.58%
Negative revenue growth while SMR.AX stands at 16.84%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
46.64%
Positive gross profit growth while SMR.AX is negative. John Neff would see a clear operational edge over the competitor.
191.76%
Positive EBIT growth while SMR.AX is negative. John Neff might see a substantial edge in operational management.
90.24%
Operating income growth 1.25-1.5x SMR.AX's 71.21%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
153.85%
Positive net income growth while SMR.AX is negative. John Neff might see a big relative performance advantage.
154.17%
Positive EPS growth while SMR.AX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
154.17%
Positive diluted EPS growth while SMR.AX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.57%
Share reduction while SMR.AX is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.57%
Reduced diluted shares while SMR.AX is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
169.21%
OCF growth above 1.5x SMR.AX's 18.53%. David Dodd would confirm a clear edge in underlying cash generation.
133.22%
FCF growth above 1.5x SMR.AX's 46.68%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
-56.59%
Negative 5Y CAGR while SMR.AX stands at 228.45%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-72.78%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
117.39%
10Y OCF/share CAGR under 50% of SMR.AX's 1942.30%. Michael Burry would worry about a persistent underperformance in cash creation.
144.23%
Below 50% of SMR.AX's 1106.93%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-87.51%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
101.21%
Positive 10Y CAGR while SMR.AX is negative. John Neff might see a substantial advantage in bottom-line trajectory.
119.90%
Positive 5Y CAGR while SMR.AX is negative. John Neff might view this as a strong mid-term relative advantage.
-94.42%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-55.05%
Negative equity/share CAGR over 10 years while SMR.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
62.39%
Equity/share CAGR of 62.39% while SMR.AX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
525.13%
Equity/share CAGR of 525.13% while SMR.AX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
2.37%
Below 50% of SMR.AX's 30.82%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Firm’s AR is declining while SMR.AX shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
82.91%
Inventory growth of 82.91% while SMR.AX is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
-5.14%
Negative asset growth while SMR.AX invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-1.07%
We have a declining book value while SMR.AX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-2.47%
We’re deleveraging while SMR.AX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
12.63%
SG&A declining or stable vs. SMR.AX's 322.56%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.